[Click e-Stock] "Metabiomed Achieves Sales Growth for 20 Consecutive Quarters"

On November 19, Eugene Investment & Securities analyzed that Metabiomed has seen its sales increase year-on-year for 20 consecutive quarters.

In the third quarter of this year, Metabiomed achieved sales of 23.5 billion KRW and an operating profit of 5.1 billion KRW. Compared to the same period last year, these figures represent increases of 1.7% and 32.0%, respectively.

Park Jongseon, a researcher at Eugene Investment & Securities, explained, "Although the dental division's sales decreased by 5.0% year-on-year, the suture division's sales increased by 6.3% compared to the same period last year." He added, "It is positive that while sales saw only a slight increase, operating profit improved significantly."

He continued, "With the suture division growing steadily, we expect a recovery in the dental division's performance, and the company is also entering the materials business in earnest."

Metabiomed is estimated to achieve sales of 26.8 billion KRW and an operating profit of 6.2 billion KRW in the fourth quarter of this year. This represents increases of 16.4% and 27.4%, respectively, compared to the same period last year.

Researcher Park analyzed, "The company plans to complete its Materials Innovation Center by the end of this year," and "The current share price is trading at a price-to-earnings ratio (PER) of 8.7 times based on this year's earnings, which is significantly discounted compared to the average PER of 19.2 times for domestic peers."

This content was produced with the assistance of AI translation services.